The economic exchange between Cuba and the United States is taking small steps forward, but taking into consideration the body of laws that have governed it for more than fifty years, these steps could be compared to miles.
Another such step forward was made when Joaquín Viso, chief executive of Grupo VL pharmaceutical company, brought forward the idea of Puerto Rico becoming a platform for processing different Cuban medical products.
Considered one of the most influential businessmen in the pharmaceutical world, Viso told the Diario Nuevo Día newspaper that the Puerto Rican private sector could make the corresponding analysis of the set of regulations, with the support of entities such as the Science, Technology and Research Trust.
That would be a secure way for Cuban pharmaceutical products to enter U.S. territory, supported by a productive platform with 50-plus years’ experience, according to the Puerto Rican press.
In addition to Puerto Rican businesspeople, other U.S. entities have shown interest in the Cuban pharmaceutical products as is the case of the Roswell Park Cancer Institute which has just asked permission from the Food and Drug Administration (FDA) to begin commercializing CimaVax, a lung cancer vaccine.
This vaccine is the result of 25 years of research work at Havana’s Molecular Engineering Center, and the Roswell Institute hopes to begin conducting clinical tests within a year at the latest.
During the recently closed 33rd edition of the Havana International Trade Fair, the BioCubaFarma company and the Servicios Médicos de Cuba S.A. trading company promoted services such as the comprehensive program for the attention given to diabetic patients and the program for cancer prevention, research and treatment.
The project known as Medical Services, which offers high-quality specialized medical treatments, is the result of the joint work by 47 institutions, and has the capacity to treat 800 patients all over the country.
Moreover, there are projects for improving foreign patients’ quality of life, preventive strategies through the use of vaccines, and diagnostic services with modern medical equipment.
Heberprot-P, the only drug of its kind for treating diabetic foot ulcers –in the majority of cases preventing foot amputations- is another leading product of the Cuban pharmaceutical industry.
Similarly attractive to leading business companies represented at the fair were the kits against cervical and prostate cancer, and the smear test kit.Share on FB Share on TT